Drug Database
FO

folic acid + vitamin B6 + vitamin B12 + primorine (Folmor)

✓ Approved

Zylera · Small Molecule · Small Molecule

What is folic acid + vitamin B6 + vitamin B12 + primorine?

folic acid + vitamin B6 + vitamin B12 + primorine is a small molecule developed by Zylera. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesFolmor
CompanyZylera
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

folic acid + vitamin B6 + vitamin B12 + primorine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved

Related Research Articles

PubMedFood chemistry2026-08-30

Vitamer-specific determination of vitamin B12 in food matrices: Analytical methodologies, challenges and future perspectives.

Deng Ligang L, Cao Li L, Ding Min M, Yang Zhaowei Z et al.

Vitamin B12 occurs in diverse food matrices, but reported concentrations often vary beyond expected biological differences because analytical workflows may quantify different measurands. This review integrates occurrence data from animal-derived, marine, fermented and plant-derived foods and critically evaluates methods ranging from microbiological and binding-based assays to HPLC, LC-MS/MS and stable isotope dilution. Particular attention is given to corrinoid analogue discrimination, cyanidation-induced measurand redefinition, native-vitamer instability, matrix effects, calibration strategies and vitamer-dependent cleanup. Recent cyanide-free UHPLC-MS/MS evidence shows that structural selectivity alone cannot compensate for inadequate control of extraction, photoconversion or form-dependent recovery. To improve transparency and inter-study comparability, we propose a three-level reporting framework based on explicit measurand definition, complete workflow description and vitamer-specific validation evidence.

PubMedCureus2026-08-30

Association of Vitamin D Deficiency With Cardiometabolic and Renal Outcomes in Patients With Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.

Imran Adnan A, Waris Hafiz Abdul HA, Khan Tanoli Sikander S, Raza Muhammad Tabish MT et al.

Autoimmune rheumatic diseases (ARDs) are chronic immune-mediated diseases associated with increased cardiovascular and renal morbidity. Vitamin D deficiency is common in these disorders and may coexist with inflammation, immune dysregulation, endothelial dysfunction, and impaired vascular and renal homeostasis. This systematic review and meta-analysis evaluated the association of vitamin D deficiency with adverse cardiometabolic and renal outcomes in ARDs. PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar were searched from inception through March 31, 2026, without language restrictions. Observational studies that measured serum 25-hydroxyvitamin D (25(OH)D) and reported cardiometabolic, cardiovascular, renal, or cardiorenal outcomes were eligible. Two reviewers independently conducted study selection, data extraction, and quality assessment. Compatible outcome-specific estimates were pooled using constrained maximum-likelihood random-effects models with Hartung-Knapp inference. Hazard ratios (HRs) and correlation coefficients were examined independently. Eighteen studies met the eligibility criteria, and four independent cohorts contributed to at least one quantitative synthesis. Vitamin D deficiency was associated with higher all-cause mortality (pooled HR 1.95, 95% confidence interval (CI) 1.36-2.79). The pooled association with cardiovascular events was imprecise (HR 2.20, 95% CI 0.52-9.25). Serum 25(OH)D was inversely but inconclusively correlated with proteinuria in pediatric systemic lupus erythematosus (r = -0.47, 95% CI -0.98 to 0.85). Cardiometabolic studies generally reported adverse metabolic and vascular findings but could not be pooled because of incompatible effect measures. Vitamin D deficiency was associated with higher mortality and greater cardiometabolic and renal disease burden; however, cardiovascular-event and proteinuria estimates remained inconclusive. Observational designs, residual confounding, heterogeneous definitions, and few compatible studies precluded causal conclusions. Prospective studies and randomized trials are required to determine whether correcting vitamin D deficiency improves clinical outcomes.

PubMedPediatric health, medicine and therapeutics2026-08-30

Vitamin D Supplementation and Serum 25-Hydroxyvitamin D Response in Infants and Children: A Narrative Review.

Vieth Simon S

Vitamin D deficiency remains common among infants and young children, particularly in higher latitudes and among exclusively breast-fed infants. Although routine supplementation is widely recommended, variability in achieved serum 25-hydroxyvitamin D [25(OH)D] concentrations has been reported across pediatric populations. Understanding the consistency of biochemical response across diverse pediatric settings remains clinically relevant for both research and supplementation practice. To summarize evidence from pediatric clinical studies utilizing a standardized vitamin D formulation and to assess the magnitude and consistency of serum 25(OH)D response across independent investigator-initiated studies. Relevant studies were identified through company-supported research records and a supplementary PubMed search. Eligible publications were published between 2010 and 2020 and included infants or children ≤18 years receiving vitamin D supplementation with reported baseline and follow-up 25(OH)D concentrations. Studies were required to explicitly identify the study formulation and report serum 25(OH)D outcomes. A narrative synthesis approach was applied. Seven studies (Canada, Australia, Vietnam, and Mongolia; total n ≈ 3,800) met inclusion criteria. Supplementation doses ranged from 400 IU/day to 14,000 IU/week across study durations of 1-12 months. Mean baseline 25(OH)D concentrations (≈53 nmol/L) increased to ≈75 nmol/L (mean Δ ≈22 nmol/L). Daily supplementation at 400 IU achieved sufficiency in the majority of infants, while higher-dose regimens produced proportionally greater increases. No study reported clinically significant adverse events attributable to supplementation. Vitamin D supplementation produced consistent and clinically meaningful increases in serum 25(OH)D concentrations across diverse pediatric populations. The approximately 20-25 nmol/L increase observed across the included studies was broadly consistent with published pediatric vitamin D supplementation literature. These findings support current supplementation practices while highlighting the reproducibility of biochemical response across independent pediatric research settings.

PubMedInternational journal of cardiology. Cardiovascular risk and prevention2026-08-30

Comment on "Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease: From molecular mechanisms to clinical application".

Mi Shiting S, Guo Xinru X, Chen Tielong T

PubMedCaspian journal of internal medicine2026-08-30

Vitamin C intake is a novel potential therapeutic approach in the secretion of adiponectin and in the treatment of abdominal obesity.

Ghanwat Ganesh H GH, Hendre Anup S AS, Sontakke Ajit V AV, Yadav Bhagyashri B et al.

The prevalence of abdominal obesity is increasing rapidly worldwide and is a leading cause of morbidities and mortalities. Abdominal obesity is associated with various health complications including insulin resistance (IR), type 2 diabetes etc. The present research studied the outcome of VC intake on adiponectin (ACRP30) levels and its relationship with waist circumference (WC) and IR. The present study was carried out on a total of 80 subjects. 42 obese (20 males and 22 females) and 38 non-obese (19 males and 19 females) were enrolled into two groups. Vitamin C (500 mg) was provided to all study subjects and instructed to consume it three times a day over a period of 90 consecutive days. Fasting blood samples were collected at the baseline and end of the study. Adiponectin levels were measured. Data were analyzed by using a two-tailed Student's t-test. Vitamin C supplementation significantly increased serum adiponectin (ACRP30) levels in obese males (P = 0.0485), obese females (P = 0.0235), non-obese males (0.0457), and non-obese females (0.0245). Adiponectin is inversely correlated with WC and IR. No significant differences were found in the levels of serum adiponectin between study participants gender-wise. 500 mg of vitamin C intake, three times a day for 90 days, is a novel potential therapeutic approach to restore the capacity of adipose tissue in secreting adiponectin and for the treatment of abdominal obesity and allied complications.

PubMedJournal of nutritional science and vitaminology2026-08-30

Orally Administered Vitamin D Ameliorates Cognitive Decline in Early Stage of Vitamin D Deficiency.

Furukawa Taichi T, Ogiwara Maiko M, Ohinata Kousaku K

Vitamin D (VD) deficiency has been associated with cognitive impairment; however, the mechanisms underlying this relationship remain unclear. In this study, we examined the impact of dietary VD deficiency on cognitive function and explored the potential involvement of gastrointestinal signaling pathways independently of changes in circulating VD levels. Mice fed a VD-deficient (VD-Def) diet exhibited impaired cognitive performance in behavioral tests, including the novel object recognition test and the object location test, despite unchanged circulating 25-hydroxyvitamin D [25(OH)D] levels. Notably, this cognitive impairment was ameliorated by oral, but not intraperitoneal, administration of VD, indicating a route-dependent effect. Furthermore, the cognitive improvement induced by oral VD was abolished by oral administration of methyllycaconitine, an α7 nicotinic acetylcholine receptor (α7nAChR) antagonist, whereas intraperitoneal administration had no effect. These findings suggest that α7nAChRs via the gastrointestinal tract are required for the cognitive benefits of orally administered VD. Collectively, our results demonstrate that VD deficiency can impair cognitive function independently of systemic VD depletion and metabolic changes, and highlight a previously unrecognized role of gastrointestinal cholinergic signaling in mediating the cognitive effects of VD.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about folic acid + vitamin B6 + vitamin B12 + primorine